Course Catalog

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Kamel Abou Hussein, MD; Kimberly Ku, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Kamel Abou Hussein, MD; Sushil Bhardwaj, MD, FACP

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Syma Iqbal, MD; Shiven B. Patel, MD, MBA, FACP

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Daniela A. Bota, MD, PhD; Benjamin Scheier, MD

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

Andrew A. Lane, MD, PhD; Marlise Luskin, MD, MSCE; Kendra Sweet, MD

Choosing Appropriate Covid-19 Prevention Strategies

Charles Vega, MD, FAAFP; Stefan Gravenstein, MD, MPH; Elie Saade, MD, MPH

Burst CME Part III: Managing Fluid Overload to Reduce Patient Burden in CKD and HF

Amir Kazory, MD, FASN, FAHA

Burst CME Part II: Current and Emerging Treatment Options for Managing Edema in CKD and HF

Stephen Greene, MD

Burst CME Part I: Reducing Fluid Overload in Early-Stage CKD and HF

Katherine DiPalo, PharmD, MBA, MS

𝘒𝘙𝘈𝘚-Targeted Therapies in Gynecologic Oncology

David S. Hong, MD; Alison Schram, MD

OncoBytes Adaptive Learning Pathways™: Decoding Precision Diagnostics and Targeted Therapies in Glioma

Vinay K. Puduvalli, MD; Ruham Nasany, MD; Angela Waanders, MD, MPH, MS

𝘒𝘙𝘈𝘚-Targeted Therapies in GI Malignancies

David S. Hong, MD; Shubham Pant, MD, MBBS

𝘒𝘙𝘈𝘚-Targeted Therapies in NSCLC

David S. Hong, MD; Kathryn C. Arbour, MD

So Cal 2026 Postgame: Live Cases and Conversations™: Improving Identification and Management of Patients with Tardive Dyskinesia

Gustavo Alva, MD; Carey Martin, PMHNP, FNP, DNP

So Cal 2026 Postgame: Integrating Glutamatergic Agents to Advance Care for Patients with MDD

Jason Kellogg, MD; Gustavo Alva, MD

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

Benjamin P. Levy, MD; Laura Alder, MD; Beth Sandy, MSN, CRNP, FAPO

Cases and Conversations: Castleman Disease in Practice—Recognizing, Classifying, and Treating a Rare Disorder

Matthew Lunning, DO, FACP; Sudipto Mukherjee, MD, PhD, MPH; Frits van Rhee, MD, PhD, MRCP (UK), FRCP...

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Kamel Abou Hussein, MD; Kit Y Lu, MD

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Virginia Kaklamani, MD, DSc; Denise Yardley, MD, GCRA

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

December 4, 2026

Community Practice Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer

Virginia Kaklamani, MD, DSc; Komal Jhaveri, MD, FACP

Show Me the Data: Immunotherapy Across the Hepatobiliary Cancer Continuum—From Embolization-Eligible HCC to Advanced Biliary Tract Cancers

November 5, 2026

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

Kamel Abou Hussein, MD; Yan Ji, MD, PhD

Project ECHO®: Applying PD-L1 Testing in mTNBC: Making Sense of Biomarker-Driven Frontline Care

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Francesca Gany, MD, MS; Hannah Y. Wen, MD, PhD

Show Me the Data™: HER2-Mutant NSCLC in Transition — Translating Evidence to Practice

October 26, 2026

Join Us at The Pathology Meeting in Las Vegas

October 4-6, 2026

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

SriniVas R. Sadda, MD, FARVO; Hong-Uyen Hua, MD; Adrienne W. Scott, MD, FASRS

BURST CME™ Activity 3: Exploring Combination Strategies in HR+/HER2– MBC: Where Do Oral SERDs Fit In?

Erica L. Mayer, MD, MPH; Jason Aboudi Mouabbi, MD

Expert Illustrations & Commentaries™: The Science of Extended Durability

Talia Kaden, MD; Diana Do, MD

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Rajwanth Veluswamy, MD, MSCR; Alison Schram, MD; Brian M. Wolpin, MD, MPH

Community Oncology Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

SoCAL 2026: Integrating Motivational Interviewing Techniques to Overcome Barriers to the Use of a Long-Acting Injectable Agent in Patients With Schizophrenia

Gerald Maguire, MD; Jacob Hanaie, PharmD, APh, BCPP; Charles Nguyen, MD, DFAPA

SoCAL 2026: PER Regional Psychiatry Series: Optimizing Treatment for Difficult-to-Treat Depression: The Role of Vagal Nerve Stimulation Therapy

Gus Alva, MD, DFAPA; Lara Shirikjian, DO

Project ECHO®: From Evidence to Action: Integrating New ADC Approaches to Optimize Treatment Sequencing in mTNBC

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ya Haddy Sallah, MD, MPH

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

December 11, 2026

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Lori A. Leslie, MD; Sushil Bhardwaj, MD, FACP

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Seth A. Wander, MD, PhD; Reshma L. Mahtani, DO; Shanu Modi, MD; Joyce O’Shaughnessy, MD

Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Joyce O’Shaughnessy, MD; Sarat Chandarlapaty, MD, PhD; Mitchell Elliott, MD, FRCPC; Seth A. Wander, ...

Evaluating Clinical Trials in Retinal Disease: Essentials for Eyecare Professionals

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 2)

OncoBytes Microlearning Pathways: New Directions in Triple-Negative Breast Cancer – Practice-Ready Updates and Expert Insights Into Recent Therapeutic Breakthroughs – Nursing (Part 1)

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Introducing Novel Treatment Paradigms for Metastatic TNBC

Aditya Bardia, MD, MPH, FASCO; Alexis LeVee, MD

Key Considerations for Health Equity and Patient-Centered Care in TNBC

Aditya Bardia, MD, MPH, FASCO; Kathryn E. Post, PhD, ANP-BC

Current Approaches and Future Directions for Early-Stage TNBC

Nour Abuhadra, MD; Antonio Giordano, MD, PhD

From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC

William J. Gradishar, MD, FASCO, FACP; Kamel Abou Hussein, MD

Rapid Reviews in Retina™: 2026 Bimonthly Updates: Part Two — Safety

Hong-Uyen Hua, MD

Clinical Consultations: Comprehensive Management of Obesity as a Chronic Disease: New and Emerging Strategies

Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS; Robert Busch, MD

“D” is for Diagnosis™: Seeking the Cause of Abdominal Pain

Brendan McGuire, MD, MS; Herbert Bonkovsky, MD